COYA

8-K - Coya Therapeutics, Inc. (0001835022) (Filer)

OLE planned in response to requests from ALSTARS investigators and participantsEligible participants completing 48 weeks of treatment will have the opportunity to continue receiving COYA 302Cash runway guidance remains unchanged into the second half of 2027, beyond anticipated ALSTARS topline data readout in early Q2Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced plans to initiate an open-label extension (OLE) of the Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302 for the treatment of amyotrophic latera

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced the company will be participating in a panel discussion at Chardan's 10th Annual Healthcare Conference taking place on October 20 in New York.Panel Details:Title: Targeting Neurodegenerative & Neuromuscular Disease: ALS, DMD, Alzheimer's & Parkinson'sTime: 2:00 PM ETModerator: Keay Nakae, Senior Research Analyst at ChardanCoya Participant: Fred Grossman, DO, President & Chief Medical Officer of Coya TherapeuticsCoya’s management team will be available for one-on-one

8-K - Coya Therapeutics, Inc. (0001835022) (Filer)

120th participant has been enrolled in ALSTARS trial achieving target enrollment Additional eligible participants already in active screening will be allowed to enroll Topline data from 24-week double-blind treatment phase on track for early Q2 2027 Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced full enrollment of the planned 120 participants in the Company’s Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, Coya’s combination of proprietary low-dose IL-2 and CTLA-4 Ig, for the potential treatmen

8-K - Coya Therapeutics, Inc. (0001835022) (Filer)

Based on current screening and enrollment rates, topline data anticipated in early Q2 2027 Additional participants continue to roll over into the active extension arm of the trial COYA 302 has received FDA Fast Track designation for the treatment of ALS Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced that the 100th patient has been enrolled in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, Coya’s combination of proprietary low-dose IL-2 and CTLA-4 Ig, for the treatment

Study results showed complementary immunomodulatory effects of COYA 303, a combination of proprietary low-dose IL-2 (LD-IL2) and a GLP-1 Receptor Agonist (GLP-1RA), compared to either LD-IL2 or GLP-1RA as monotherapyGLP-1RA attenuated myeloid expansion and inflammatory transcriptional responses, whereas LD-IL2 increased Treg numbers and transcripts associated with Treg stability and suppressive functionCoya believes findings support further evaluation of COYA 303 and combination approaches in addressing Alzheimer’s disease and other complex neurodegenerative indicationsCoya will continue to pursue non-dilutive avenues and potential partnerships to advance the COYA 303 programCoya Therapeutic

10-Q - Coya Therapeutics, Inc. (0001835022) (Filer)

8-K - Coya Therapeutics, Inc. (0001835022) (Filer)

8-K/A - Coya Therapeutics, Inc. (0001835022) (Filer)

SCHEDULE 13G/A - Coya Therapeutics, Inc. (0001835022) (Subject)

8-K - Coya Therapeutics, Inc. (0001835022) (Filer)

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces that the Company will present an overview of the ongoing ALSTARS trial, outlining its design and approach to targeting neuroinflammation, at the European Network to Cure ALS (ENCALS) Meeting 2026 which will take place June 24–26, 2026, in Madrid, Spain. The details for the poster presentation, which will be presented by Tyrell Simkins, D.O., Ph.D., Senior Director, Clinical Development, are below: Poster Title: ALSTARS: A Precision Immunomodulatory Phase 2 Trial Of C

Virtual Live Webinar Set for Wednesday, June 24 at 4 p.m. ET / 1 p.m. PT Will be moderated by Solomon Wilcots and feature discussion and insights from CNS experts, Stanley H. Appel, M.D., Fred Grossman D.O. and leading sports agent and concussion awareness advocate Leigh Steinberg Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced it will host a live webinar on June 24, 2026 at 4 p.m. ET / 1 p.m. PT. Titled ‘Beyond the Hit: How Repetitive Head Trauma, Inflammation, and Neurodegenerative Disease Intersect'

Patients with ALS who have completed the 24-week, double-blind, placebo-controlled Phase of the ALSTARS Trial, have entered the 24-week blinded extension period, during which all participants receive COYA 302 Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the initiation of the blinded extension phase of the ALSTARS Trial (ClinicalTrials.gov Identifier: NCT07161999). Patients who complete the 24-week placebo-controlled double-blind phase enter the blinded extension phase of the study and continue on their regimen from the first phase; placebo patients are re-randomized

Roth Capital initiated coverage of Coya Therapeutics with a rating of Buy and set a new price target of $12.00

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces that the Company will present an overview of the ongoing ALSTARS trial, outlining its design and approach to targeting neuroinflammation, at the 5th ALS Drug Development Summit which will take place June 2–4, 2026, in Boston, MA. The details for the poster presentation, which will be presented by Tyrell Simkins, D.O., Ph.D., Senior Director, Clinical Development, are below: Poster Title: ALSTARS: A Precision Immunomodulatory Phase 2 Trial of COYA 302 Targeting Regula

DEFA14A - Coya Therapeutics, Inc. (0001835022) (Filer)

DEF 14A - Coya Therapeutics, Inc. (0001835022) (Filer)

8-K - Coya Therapeutics, Inc. (0001835022) (Filer)

424B5 - Coya Therapeutics, Inc. (0001835022) (Filer)

10-Q - Coya Therapeutics, Inc. (0001835022) (Filer)

8-K - Coya Therapeutics, Inc. (0001835022) (Filer)

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces its financial results for the quarter ended March 31, 2026 and provides a corporate update. "We are off to a strong start in 2026, building on the clinical and scientific progress achieved last year," said Arun Swaminathan, Ph.D., Chief Executive Officer of Coya. "The ALSTARS trial is now in full recruitment mode, and we maintain our guidance for a 1Q 2027 topline readout. With a solid foundation and balance sheet in place we are well positioned to deliver on our prior